Société BioCryst Pharmaceuticals, Inc.
Actions
BCRX
US09058V1035
Recherche biotechnologique et médicale
Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
5,15 USD | +2,79 % | -5,85 % | -14,02 % |
Métier
Nombre d'employés: 536
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100,0
%
| 271 | 100,0 % | 331 | 100,0 % | +22,37 % |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
87,0
%
| - | - | 288 | 87,0 % | - |
Non-United States
11,4
%
| - | - | 38 | 11,4 % | - |
Global
1,6
%
| 271 | 100,0 % | 5 | 1,6 % | -98,00 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/01/07 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02/04/20 |
Michael Jones
DFI | Director of Finance/CFO | 54 | 01/01/11 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/22 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/09/19 |
Philip George
PRN | Corporate Officer/Principal | - | 01/09/22 |
Corporate Officer/Principal | - | 01/01/15 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 01/08/15 |
Human Resources Officer | - | 01/11/18 | |
Salisa Hauptmann
LAW | General Counsel | - | 01/01/21 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27/02/20 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/01/07 |
Director/Board Member | 60 | 26/07/21 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 04/01/19 |
Director/Board Member | 69 | 10/10/11 | |
Nancy Hutson
CHM | Chairman | 74 | 20/01/12 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/09/19 |
Steven Galson
BRD | Director/Board Member | 67 | 01/09/21 |
Theresa Heggie
BRD | Director/Board Member | 63 | 03/12/18 |
Amy McKee
BRD | Director/Board Member | 52 | 20/09/21 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 206 149 929 | 199 790 568 ( 96,92 %) | 0 | 96,92 % |
Coordonnées société
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSecteur
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
-14,02 % | 1,06 Md | |
+2,56 % | 108 Md | |
+10,02 % | 104 Md | |
+7,89 % | 23,66 Md | |
-11,91 % | 22,1 Md | |
-3,29 % | 19,71 Md | |
-35,98 % | 18,2 Md | |
-14,02 % | 16,19 Md | |
+4,61 % | 13,72 Md | |
+35,05 % | 12,22 Md |
- Bourse
- Actions
- Action BioCryst Pharmaceuticals, Inc. - Nasdaq
- Société BioCryst Pharmaceuticals, Inc.